Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Cross Above 200-Day Moving Average - Here's Why

Key Points

• Shares crossed above its 200-day moving average (200-day MA $56.60), trading as high as $70.97 on Wednesday with roughly 2.2 million shares changing hands.
• Multiple analysts raised price targets (Piper Sandler $110, HC Wainwright $100, B. Riley $101, Goldman to $85, Morgan Stanley $81) and the consensus rating is a Moderate Buy with a $81.67 target price.
• In the latest quarter Arrowhead reported revenue of $264.03 million (beating $225.66M est.) but missed EPS at $0.22 vs. $0.60 expected; revenue was up an extraordinary 10,461% year‑over‑year with a net margin of 18.54%.

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $56.60 and traded as high as $70.97. Arrowhead Pharmaceuticals shares last traded at $70.95, with a volume of 2,202,177 shares trading hands.

Analyst Ratings Changes

Several analysts recently commented on the stock. HC Wainwright reissued a "buy" rating and set a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, March 25th. The Goldman Sachs Group increased their price objective on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a "neutral" rating in a research report on Wednesday, January 7th. Morgan Stanley raised their price target on shares of Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the company an "equal weight" rating in a report on Wednesday, January 7th. Piper Sandler reaffirmed an "overweight" rating and set a $110.00 price target (up from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 13th. Finally, B. Riley Financial raised their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a "buy" rating in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $81.67.

Arrowhead Pharmaceuticals Stock Performance

The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.29. The company has a market cap of $9.94 billion, a PE ratio of 46.37 and a beta of 1.26. The business's fifty day moving average is $61.68 and its 200-day moving average is $56.60.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.60 by ($0.38). The business had revenue of $264.03 million during the quarter, compared to analysts' expectations of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The business's quarterly revenue was up 10461.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.39) EPS. As a group, research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 10,000 shares of the firm's stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $64.19, for a total transaction of $641,900.00. Following the sale, the insider owned 236,958 shares in the company, valued at approximately $15,210,334.02. This trade represents a 4.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.60% of the company's stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ARWR. Royal Bank of Canada raised its stake in Arrowhead Pharmaceuticals by 30.2% during the 1st quarter. Royal Bank of Canada now owns 45,239 shares of the biotechnology company's stock worth $576,000 after acquiring an additional 10,496 shares during the period. AQR Capital Management LLC bought a new stake in Arrowhead Pharmaceuticals during the 1st quarter worth approximately $514,000. Goldman Sachs Group Inc. raised its stake in Arrowhead Pharmaceuticals by 34.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company's stock worth $22,189,000 after acquiring an additional 447,456 shares during the period. Empowered Funds LLC raised its stake in Arrowhead Pharmaceuticals by 6.9% during the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company's stock worth $194,000 after acquiring an additional 979 shares during the period. Finally, Focus Partners Wealth raised its stake in Arrowhead Pharmaceuticals by 1,339.5% during the 1st quarter. Focus Partners Wealth now owns 16,252 shares of the biotechnology company's stock worth $207,000 after acquiring an additional 15,123 shares during the period. Institutional investors own 62.61% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.